文献类型：期刊文献

英文题名：Redox-responsive chondroitin sulfate-based micelle system for enhanced chemotherapy and inflammation suppression to synergistically antitumor therapy

作者：Long, Miaomiao[1,2] Chen, Weijun[3] Li, Jie[3] Kong, Weibo[3] Su, Min[4,5] Qiu, Lipeng[3] Cheng, Xian[1] Bi, Liangwu[1]

第一作者：Long, Miaomiao

通信作者：Cheng, X[1];Bi, LW[1];Su, M[2]

机构：[1]Chinese Acad Forestry, Inst Chem Ind Forest Prod, Nanjing 210042, Peoples R China;[2]Wuxi Higher Hlth Vocat Technol Sch, Dept Pharm, Wuxi 214028, Peoples R China;[3]Jiangnan Univ, Sch Life Sci & Hlth Engn, Wuxi 214122, Peoples R China;[4]Cent South Univ, Hunan Clin Med Res Ctr Accurate Diag & Treatment E, Affiliated Canc Hosp, Xiangya Sch Med,Hunan Canc Hosp, Changsha 410013, Peoples R China;[5]Hunan RunKun Pharmaceut Co Ltd, Yuehang 414003, Peoples R China

年份：2025

卷号：311

外文期刊名：INTERNATIONAL JOURNAL OF BIOLOGICAL MACROMOLECULES

收录：;EI(收录号：20251918373604);Scopus(收录号：2-s2.0-105004260382);WOS:【SCI-EXPANDED(收录号:WOS:001488773600001)】；

基金：Acknowledgements This work was supported by the Research Project of Wuxi Health Commission (M202323) , Science and Technology Innovation Program of Hunan Province (2024RC3284) , Changsha Municipal Natural Science Foundation (kq2208152) and National Natural Science Foundation of China (32201512) .

语种：英文

外文关键词：Rosmarinic acid; Chondroitin sulfate; Doxorubicin; Micelles; Synergistic therapy

摘要：According to the close association between cancer and inflammation demonstrated in clinical data, the strategy of synergistic anti-tumor and anti-inflammatory therapy shows promising potential. However, challenges remain in the synthesis and development of co-delivery systems for synergistic therapy. Herein, an amphiphilic chondroitin sulfate-rosmarinic acid polymeric prodrug was synthesized, and then combined with DSPE-PEG to encapsulate doxorubicin, forming a redox-responsive nanomicelle (PRSC/DOX) delivery system. PRSC/DOX exhibited a particle size of 188.6 nm and remained stable in PBS for at least 7 days. PRSC/DOX was internalized into tumor cells via CD44 receptor-mediated endocytosis, and degraded by intracellular glutathione to release the drugs. The released doxorubicin killed tumor cells through chemotherapy, and rosmarinic acid inhibited tumor cell growth by suppressing inflammation levels in the tumor microenvironment. In vivo experiments showed a statistically significant decrease in the inflammation levels in mice, along with a considerable reduction in tumor volume. Consequently, the PRSC/DOX significantly enhanced antitumor efficacy through a synergistic therapy of chemotherapy and inflammation suppression.